步长制药：深耕中药出海，厚植公益底色。彰显企业担当！

Core Viewpoint - The company is accelerating its internationalization and innovation efforts, with over 170 products included in the 2025 National Medical Insurance Directory, and is focusing on expanding its global market presence through strategic partnerships and product registrations [1][3][4]. Group 1: Product Development and Innovation - The company has 73 exclusive products in the 2025 National Medical Insurance Directory, including 63 traditional Chinese medicines, 9 chemical drugs, and 1 vaccine [1]. - The company is advancing its first-class new drug, Efparepoetin alfa, which has a cumulative R&D investment of approximately 51.24 million RMB as of September 30, 2025, and is expected to have significant market potential as it is the first of its kind in China [3]. - The company has successfully registered multiple products in various countries, including Malaysia, Canada, and Mongolia, indicating a strong international market strategy [5][6]. Group 2: Policy Support and Market Expansion - A recent guideline issued by five government departments aims to enhance the overseas service ecosystem for Chinese enterprises, which will support the company's international expansion efforts [4]. - The company has expanded its product sales to numerous countries and regions, including the United States, Canada, and several countries in Asia, Europe, and Africa, with ongoing registration efforts in Australia, Brazil, and the UAE [5]. Group 3: Corporate Social Responsibility - The company has contributed nearly 33 billion RMB in taxes, supporting local economic development and demonstrating its commitment to social responsibility [7]. - The "Together, Build a Chinese Heart" project has been ongoing for 18 years, providing medical assistance to Tibetan and minority communities, showcasing the company's dedication to social welfare [8][10]. - The company emphasizes long-term commitment to public welfare, aiming to set an industry example in corporate citizenship [7][10].